Interestingly, a recent clinical trial compared the efficacy of tocilizumab versus adalimumab (anti-TNF-α antibody) as monotherapy in RA and revealed a significant greater disease improvement in patients treated with tolicizumab [214]. The gene discussed is TNF; the disease is rheumatoid arthritis.